Loading organizations...
Based in London, England, CoMind develops non-invasive neurotechnology and light-based sensors designed to measure multidimensional brain activity and neurophysiological signals directly at the patient bedside. The company's proprietary artificial intelligence platform, known as CoVision, processes these complex physiological signals to provide predictive neurological insights to clinicians, surgeons, and nurses. This integrated hardware and software system supports critical medical applications across intensive care units, emergency rooms, and complex surgical environments for continuous neurological observation. Operating with a workforce of approximately 61 employees, the enterprise has historically secured $60.1 million in venture and grant funding to advance its optical neuromonitoring devices. To support its ongoing clinical development, CoMind is backed by several prominent institutional investors, including Octopus Ventures, LocalGlobe, Crane Venture Partners, and AlbionVC. The London-based medical device company was founded in 2018 by entrepreneur James Dacombe.
CoMind has raised $87.0M across 2 funding rounds.
CoMind has raised $87.0M in total across 2 funding rounds.
CoMind has raised $87.0M in total across 2 funding rounds.
CoMind's investors include Entrepreneur First, First Star Ventures, LocalGlobe, No Label Ventures, Singular, Roxanne Varza, Saturnin Pugnet.
CoMind has raised $87.0M across 2 funding rounds. Most recently, it raised $60.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $60M Series A | — | Entrepreneur First, First Star Ventures, LocalGlobe, NO Label Ventures, Singular, Roxanne Varza, Saturnin Pugnet | Announced |
| Dec 1, 2022 | $27M Series A | — | First Star Ventures, LocalGlobe | Announced |
CoMind is a London-based neurotechnology startup founded in 2018, developing non-invasive neurosensing platforms for healthcare, particularly in neuroscience and neurology.[1][2][3] Its core product uses laser-based optical technology to enable real-time monitoring of key brain parameters like cerebral blood flow, intracranial pressure, brain tissue oxygen saturation, and cerebral metabolism, addressing limitations in current invasive or inaccurate bedside monitoring.[4][7] CoMind serves clinicians, surgeons, and healthcare professionals treating complex neurological conditions, solving the problem of inaccessible neurophysiological data to improve patient outcomes across the care continuum.[1][3][5] The company has raised funding from investors like Octopus Ventures, LocalGlobe, and Crane Venture Partners, employs 51-200 people, and shows growth through active operations and recent account filings up to 2024.[2][6]
CoMind Technologies Limited was incorporated on December 17, 2018, in London, England, as a private limited company focused on other information technology service activities.[6] Founded by James Dacombe, who serves as CEO and Chairman, the leadership team includes CTO Simon Morling, Chief Scientific Officer Dr. Rob Cooper, Chief Commercial Officer Chema Garcia-Soto, CFO Kevin Walsh, Chief Medical Officer Dr. Marc Bloom, General Manager Morgan Lockyer, and Principal Engineer Dr. Dawid Borycki—all highly skilled experts driving innovation in neuromonitoring devices and neural interfaces.[3] The idea emerged from gaps in neuroscience monitoring, where existing solutions are invasive, expensive, or imprecise; CoMind leverages non-invasive tech inspired by gaming, LiDAR, and interferometric optics to enable precise, affordable, portable sensing.[1][2][4] Early traction includes backing from prominent VCs and positioning as a high-potential player in medtech, with technology designed for clinical therapies, medical education, and eventual wearable applications.[1][2]
CoMind rides the neurotechnology wave, intersecting deep tech, biotech, hardware, and health data analytics amid rising demand for precise brain monitoring in aging populations and neurological diseases like Parkinson's.[1][2] Timing aligns with advances in optical sensing (e.g., LiDAR) and non-invasive medtech, accelerated by post-pandemic focus on remote/portable diagnostics and AI-driven neural interfaces.[4] Market forces favoring it include regulatory pushes for faster medtech development (e.g., digital twins like competitors Virtonomy), huge potential in neurosurgery precision (vs. invasive rivals like Inbrain or microrobots like Robeauté), and investor interest in healthech from firms like AlbionVC.[1] CoMind influences the ecosystem by catalyzing affordable neuroscience applications, potentially disrupting medtech R&D, clinical care, and brain-computer interfaces.[2]
CoMind is poised to scale its platform toward FDA/CE approvals, wearable devices, and expanded clinical trials, targeting neurosurgery, ICU monitoring, and consumer neural tech.[2][4] Trends like AI integration for closed-loop therapies and precision medicine will amplify its impact, especially as non-invasive neurotech matures amid global brain health initiatives.[1][7] Its influence may evolve from niche medtech innovator to ecosystem enabler, powering neural apps and partnerships—ultimately redefining brain measurement as accessibly as vital signs monitoring today.[3] This positions CoMind at the forefront of a multi-billion-dollar neurotech frontier, optimizing outcomes where current tools fall short.[5]
